US

Get Takeda Pharmaceutical Alerts

Weekly insights + SMS alerts

Insilico Medicine announced Thursday that it has entered a strategic collaboration with Takeda Pharmaceutical Co. Ltd. (TAK) to use its proprietary Pharma.AI platform for discovering and advancing new drug candidates across multiple therapeutic areas.

Deal Includes Upfront Payments And Future Milestones

As part of the collaboration, Insilico will receive approximately $60 million in project initiation fees, near-term payments, and milestone payments. The company is also eligible for additional success-based preclinical, clinical, commercial, and sales milestone payments that could increase the total value of the agreement to about $600 million. In addition to these payments, Insilico stands to receive tiered royalties on future sales of any products commercialized under the collaboration.

AI Platform To Power Drug Candidate Discovery

The collaboration is aimed at identifying clinically differentiated drug candidates for promising therapeutic targets using Insilico's end-to-end Pharma.AI platform. By applying advanced generative AI models from the earliest stages of drug design, the companies intend to improve the quality of candidate molecules while optimizing them for best-in-class efficacy and safety profiles. The partnership combines Insilico's AI-driven drug discovery capabilities with Takeda's expertise in global drug development to accelerate the progression of promising therapies.

Takeda, Insilico Outline Roles In Drug Development

Under the agreement, Insilico will lead the AI-enabled discovery process, identifying molecules that meet predefined scientific and early development benchmarks. Takeda will then leverage its global development capabilities to advance selected candidates through clinical validation. The agreement also grants Takeda exclusive worldwide rights to develop, manufacture, and commercialize any novel therapeutics selected through the collaboration.